There is no official, publicly ranked “Top 10 lowest” or “worst” list of liver transplant hospitals in the United States. Ranking centers as “lowest” by volume or raw outcomes without full context is misleading and potentially harmful. Liver transplant programs vary widely in size, and the Scientific Registry of Transplant Recipients (SRTR) deliberately uses risk-adjusted metrics and often excludes or stabilizes very low-volume programs because small numbers make rates statistically unstable.
Understanding Volume and Performance in U.S. Liver Transplant Centers
There are roughly 140–150 active adult and pediatric liver transplant programs across about 40 states. According to recent OPTN/SRTR annual data:
- Roughly 30% of centers perform 25 or fewer transplants per year.
- A substantial share perform under 50–75 annually.
- High-volume centers (often >100–150+ per year) account for a disproportionate share of total national transplants (over 11,000 livers in recent years).
- National one-year graft survival for adult deceased-donor recipients is generally in the low-to-mid 90% range, with patient survival slightly higher; outcomes have improved over the past decade.
Low volume does not automatically equal poor quality. Some mid- or lower-volume programs post excellent risk-adjusted survival rates. Conversely, very high-volume centers accept sicker or more complex patients, which can affect unadjusted numbers. SRTR applies hierarchical Bayesian models that pull small-program estimates toward the national average precisely because a handful of cases can swing percentages dramatically.
Factors that produce lower-volume programs include:
- Geographic location and organ procurement organization (OPO) performance
- Focus on pediatric cases only
- VA or specialized institutional missions
- Newer or more selective programs
- Regional competition from nearby high-volume academic centers
- Resource constraints or deliberate emphasis on quality over quantity
Public data sources (SRTR Program-Specific Reports, plaintransplant.com summaries of SRTR releases, National Friends tools, and OPTN reports) show a long tail of smaller programs. Examples of centers that have appeared with relatively modest volumes in recent reporting periods include certain VA facilities, some children’s hospitals with limited adult activity, and regional centers such as those in smaller population states. Exact rankings shift with each SRTR release (typically twice yearly), and centers with very low activity may not meet the minimum case threshold for full public survival rankings.
Why a Simple “Lowest” Ranking Is Problematic
- Statistical noise — A program doing 5–15 transplants can look outstanding or poor based on chance alone.
- Patient mix — Risk adjustment accounts for MELD score, diagnosis, age, comorbidities, and donor factors. Unadjusted “lowest survival” lists can unfairly penalize centers that take higher-risk patients.
- Access vs. outcomes trade-off — Smaller programs may offer shorter travel, cultural familiarity, or faster listing for local patients even if absolute volume is low.
- Dynamic data — Volumes and outcomes change. A center low one year may expand or improve the next.
- Potential for harm — Labeling hospitals “lowest” without nuance can discourage patients from seeking evaluation at accessible centers or create unnecessary fear.
U.S. News & World Report and similar rankings focus primarily on high-performing or high-volume centers in gastroenterology/GI surgery and do not publish formal “bottom” lists for transplant programs. Forbes or other consumer rankings have shown little correlation with SRTR graft survival once volume is considered.
Practical Guidance for Patients and Families
Instead of seeking the “lowest” centers, use these steps:
- Review the latest SRTR Program-Specific Reports (srtr.org) for any center of interest. Look at risk-adjusted one-year and three-year graft and patient survival, waitlist mortality, and transplant rates relative to national benchmarks.
- Compare multiple centers, including both high-volume academic programs and regional options.
- Ask about living-donor experience, use of machine perfusion (normothermic or hypothermic), acceptance of extended-criteria or DCD donors, and multi-organ capability if relevant.
- Consider logistics: distance for evaluation and follow-up, insurance network status, and support services (social work, lodging, caregiver resources).
- Obtain second opinions. Many patients list at more than one center.
- Discuss your specific MELD score, blood type, diagnosis, and comorbidities with transplant hepatologists—the “best” center is the one that is right for you.
Smaller programs can and do deliver excellent care. Some of the highest risk-adjusted survival figures in recent SRTR cohorts have come from mid-sized rather than the absolute largest centers. The national trend toward broader use of machine perfusion and DCD organs has also allowed more programs of varying sizes to expand safely.
Conclusion
The U.S. liver transplant system includes a spectrum from very high-volume academic powerhouses to smaller regional and specialized programs. There is no authoritative public ranking of the “lowest” hospitals, and constructing one from incomplete or unadjusted data would be inaccurate and unhelpful. Volume alone is a poor proxy for quality; risk-adjusted outcomes, process measures, and individual patient fit matter far more.
Patients facing liver failure should focus on transparent SRTR data, multidisciplinary evaluation, and personalized medical advice rather than any simplified “top” or “bottom” list. Official sources—SRTR, OPTN, and direct conversations with transplant teams—remain the most reliable guides. Early referral, realistic assessment of candidacy, and informed comparison of centers give patients the best chance of a successful transplant and long-term recovery. Always verify the most current reports, as the landscape of volumes and outcomes continues to evolve.